Kyoto University Innovation Capital (Kyoto iCAP) has invested 100 million yen in Toregem Biopharma to support the development of TRG035, a pioneering dental regenerative therapy.
Overview of the Target
Founded in May 2020, Toregem Biopharma Inc. is a dental drug discovery startup originating from Kyoto University. The company has established a partnership with Kyoto University, through which they have identified the role of USAG-1, a molecule that inhibits the activity of bone morphogenetic proteins (BMPs), during the dental development processes. Their research has shown that neutralizing antibodies can lead to the recovery of missing teeth alongside alveolar bone in models of hypodontia.
Industry Overview in Japan
The biopharmaceutical industry in Japan is at the forefront of global innovation, characterized by its robust research environment and high investment in life sciences. Japan's healthcare market is also supported by a rapidly aging population, which has increased the demand for advanced medical and dental treatments. The government continually invests in healthcare initiatives, creating a fertile ground for biopharmaceutical startups, particularly in regenerative medicine and dental therapies.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Moreover, Japan's regulatory framework for drug approval is designed to facilitate faster pathways for innovative therapies. Companies can engage in colla
Similar Deals
Kyoto University Innovation Capital Co., Ltd.
invested in
Toregem Biopharma, Inc.
in 2024
in a Series B deal
Disclosed details
Transaction Size: $9M